Literature DB >> 32829400

Bacille Calmette-Guérin Vaccination in Infancy Does Not Protect Against Coronavirus Disease 2019 (COVID-19): Evidence From a Natural Experiment in Sweden.

Clément de Chaisemartin1, Luc de Chaisemartin2,3.   

Abstract

BACKGROUND: The bacille Calmette-Guérin (BCG) tuberculosis vaccine has immunity benefits against respiratory infections. Accordingly, it has been hypothesized to have a protective effect against coronavirus disease 2019 (COVID-19). Recent research found that countries with universal BCG childhood vaccination policies tend to be less affected by the COVID-19 pandemic. However, such ecological studies are biased by numerous confounders. Instead, this paper reports on a rare nationwide natural experiment that occurred in Sweden in 1975, where discontinuation of newborns' BCG vaccination led to a dramatic decrease in BCG coverage rate, thus allowing us to estimate BCG's effect without the biases associated with cross-country comparisons.
METHODS: Numbers of COVID-19 cases and hospitalizations were recorded for birth cohorts born just before and just after 1975, representing 1 026 304 and 1 018 544 individuals, respectively. We used regression discontinuity to assess the effect of BCG vaccination on COVID-19-related outcomes. On such a large population, this method allows for a precision that would be hard to achieve using a randomized controlled trial.
RESULTS: The odds ratios (95% CI) for COVID-19 cases and COVID-19-related hospitalizations were 1.0005 (.8130-1.1881) and 1.2046 (.7532-1.6560), allowing us to reject fairly modest effects of universal BCG vaccination. We can reject with 95% confidence that universal BCG vaccination reduces the number of cases by 19% and the number of hospitalizations by 25%.
CONCLUSIONS: While the effect of a recent vaccination must be evaluated, we provide strong evidence that receiving the BCG vaccine at birth does not have a protective effect against COVID-19 among middle-aged individuals.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  BCG; COVID-19; regression discontinuity

Mesh:

Substances:

Year:  2021        PMID: 32829400      PMCID: PMC7499491          DOI: 10.1093/cid/ciaa1223

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

1.  BCG vaccination potential for COVID-19: an analytical approach.

Authors:  Mina T Kelleni
Journal:  Hum Vaccin Immunother       Date:  2021-03-26       Impact factor: 3.452

Review 2.  COVID-19 and Pediatric Lung Disease: A South African Tertiary Center Experience.

Authors:  Diane M Gray; Mary-Ann Davies; Leah Githinji; Michael Levin; Muntanga Mapani; Zandiswa Nowalaza; Norbertta Washaya; Aamir Yassin; Marco Zampoli; Heather J Zar; Aneesa Vanker
Journal:  Front Pediatr       Date:  2021-01-20       Impact factor: 3.418

Review 3.  On BCG Vaccine Protection from COVID-19: A Review.

Authors:  Narges Bagheri; Hesam Montazeri
Journal:  SN Compr Clin Med       Date:  2021-03-15

Review 4.  COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa.

Authors:  Bisi Bright; Chinedum Peace Babalola; Nadia Adjoa Sam-Agudu; Augustine Anayochukwu Onyeaghala; Adebola Olatunji; Ufuoma Aduh; Patrick O Sobande; Trevor A Crowell; Yenew Kebede Tebeje; Sunny Phillip; Nicaise Ndembi; Morenike Oluwatoyin Folayan
Journal:  Global Health       Date:  2021-03-03       Impact factor: 4.185

5.  COVID-19 Severity and Neonatal BCG Vaccination among Young Population in Taiwan.

Authors:  Wei-Ju Su; Chia-Hsuin Chang; Jiun-Ling Wang; Shu-Fong Chen; Chin-Hui Yang
Journal:  Int J Environ Res Public Health       Date:  2021-04-18       Impact factor: 3.390

6.  Epitope similarity cannot explain the pre-formed T cell immunity towards structural SARS-CoV-2 proteins.

Authors:  Ulrik Stervbo; Sven Rahmann; Toralf Roch; Timm H Westhoff; Nina Babel
Journal:  Sci Rep       Date:  2020-11-04       Impact factor: 4.379

7.  On the relationship between BCG coverage and national COVID-19 outcome: could 'heterologous' herd immunity explain why some countries are better off?

Authors:  M Lerm
Journal:  J Intern Med       Date:  2020-12       Impact factor: 8.989

8.  COVID-19 and BCG: where's the challenge?

Authors:  Georges Mjaess; Eddy Lilly; Raymond Mansour; Simone Albisinni; Elie Nemr; Fouad Aoun; Thierry Roumeguere
Journal:  World J Urol       Date:  2021-01-02       Impact factor: 3.661

9.  Pneumococcal and Influenza Vaccination Rates and Pneumococcal Invasive Disease Rates Set Geographical and Ethnic Population Susceptibility to Serious COVID-19 Cases and Deaths.

Authors:  Robert Root-Bernstein
Journal:  Vaccines (Basel)       Date:  2021-05-08

Review 10.  100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19.

Authors:  Niyati Lobo; Nathan A Brooks; Alexandre R Zlotta; Jeffrey D Cirillo; Stephen Boorjian; Peter C Black; Joshua J Meeks; Trinity J Bivalacqua; Paolo Gontero; Gary D Steinberg; David McConkey; Marko Babjuk; J Alfred Witjes; Ashish M Kamat
Journal:  Nat Rev Urol       Date:  2021-06-15       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.